Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iPSC-nCAR-NK
- Development stage
- Preclinical
- Lead developer
- HebeCell
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
iPSC-nCAR-NK is a **preclinical, off-the-shelf allogeneic NK cell therapy** composed of **genetically engineered natural killer cells derived from induced pluripotent stem cells** and equipped with a **nanobody-based chimeric antigen receptor**. The program is being developed by **Proteintech** in collaboration with **HebeCell** for cancer and potentially other diseases. Its distinguishing feature is use of a proprietary **nCAR** architecture in which the antigen-recognition domain is a camelid-derived single-domain antibody fragment rather than a conventional scFv, combined with HebeCell's feeder-free, industrial-scale iPSC-to-NK manufacturing platform intended to support scalable 3D bioreactor production and off-the-shelf cell therapy supply. The specific tumor antigen targeted by iPSC-nCAR-NK has not been disclosed in the provided materials, so the therapeutic mechanism is best described as programmable antigen-directed NK-cell cytotoxic immunotherapy.
- Other names
- iPSC-derived nCAR-NKiPSC-CAR-NK
Beyond the preview
Go deeper on iPSC-nCAR-NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iPSC-nCAR-NK.